The geography of the field
Where hair-regeneration programmes are being developed, and — separately — where any of it has actually been authorised. The two maps barely overlap, which is the honest summary of this field: the work is concentrated in a handful of countries, and whether it reaches you depends on a regulator that has never heard of most of it.
Programmes in developmentAt least one authorised treatment
Where the work is done
- United States22AnaptysBio · TechnoDerma Medicines · Stemson Therapeutics · Eli Lilly · DermaLiq Therapeutics · Organon · Applied Biology · Aclaris Therapeutics · Bristol Myers Squibb · Amgen · Equillium · Priovant Therapeutics · Eirion Therapeutics · Aneira Pharma · AbbVie · Pfizer · Biosplice Therapeutics · Veradermics · Amplifica · Pelage Pharmaceuticals
- China6Jiangsu Vcare Pharmaceutical · Hope Medicine · CSPC Pharmaceutical Group · Suzhou Zelgen Biopharmaceuticals · Kintor Pharmaceutical
- South Korea4Chong Kun Dang Pharmaceutical · Addpharma · Epibiotech
- Brazil4EMS · Apsen Farmacêutica · Biolab Sanus Farmacêutica · Eurofarma Laboratórios
- Canada2Triple Hair · RepliCel Life Sciences
- Switzerland2Legacy Healthcare
- United Kingdom2GSK · HairClone
- France1Sanofi
- Japan1OrganTech
- Germany1TissUse
- Denmark1LEO Pharma
- Spain1Almirall
- Ireland1Cosmo Pharmaceuticals
- India1Sun Pharmaceutical
- Sweden1Follicum
- Singapore1ASLAN Pharmaceuticals
Where treatments are authorised
Counted from the register's approval records, which currently cover the marketed standards and the approved JAK inhibitors. Absence here means we have not recorded an authorisation, not that none exists.
- United StatesFDA5 authorised · 3 off-label
- South KoreaMFDS1 authorised
- FranceANSM, EMA7 authorised
- JapanPMDA1 authorised
- European UnionEMA3 authorised